LKT Labs

Biochemicals for Life Science Research

Swainsonine

Swainsonine

Product ID S881011
Cas No. 72741-87-8
Purity ≥98%
Product Unit SizeCostQuantityStock
1 mg $172.60 Please Inquire
5 mg $721.20 In stock
10 mg $1,299.60 Please Inquire
Bulk Quote

Quicklinks

Description

Swainsonine is an indolizidine alkaloid isolated from the fungus metharhizium anisopliae. It is an antineoplastic immunomodulator. Swainsonine restores the capacities of immunodeficient mice such that the growth and metastasis of implanted tumors are inhibited. The anti-metastatic effect may be the result of the stimulation of lymphocyte proliferation and augmentation of natural killer cell reactivity of the immune system.
Swainsonine has been found to induce apoptosis in esophageal squamous cell carcinoma and human lung cancer cells as well as C6 glioma cells.
In addition to its anti-proliferative effect on tumor cells, swainsonine has been found to potentiate cytotoxic effects of chemotherapeutic drugs such as paclitaxel and cisplatin.

Product Info

Cas No.

72741-87-8
Purity

≥98%
Formula

C8H15NO3
Formula Wt.

173.20
Chemical Name

(1S,2R,8R,8aR)-1,2,3,5,6,7,8,8a-octahydroindolizine-1,2,8-triol
IUPAC Name

(1S,2R,8R,8aR)-Octahydro-1,2,8-indolizinetriol
Synonym

SwainMoia, (1S,2R,8R,8aR)-octahydroindolizine-1,2,8-triol,       D-Swainsonine, 8A,B-INDOLIZIDINE-1,2A,8B-TRIOL,SWAINSONINE,Tridolgosir, SwainMoia,    (1S,2R,8R,8aR)-octahydro-1,2,8-indolizinetriol, 
Solubility

10 mg/ml in water, 5 mg/ml in methanol, Soluble in ethanol, DMSO, DMF (~10 mg/ml), and PBS (pH=7.2) (0.25 mg/ml).
Appearance

Beige lyophilized powder

Shipping and Storage

Store Temp

-20°C
Ship Temp

Ambient

Downloads

MSDS

S881011 MSDS PDF
Info Sheet

S881011 Info Sheet PDF

References

Mohla S, Humphries MJ, White SL, et al. Swainsonine: a new antineoplastic immunomodulator. J Natl Med Assoc. 1989, 81(10):1049-56. PMID: 2509720 PMCID: PMC2571577.

Kino T, Inamura N, Nakahara K, et al. Studies of an immunomodulator, swainsonine. II. Effect of swainsonine
on mouse immunodeficient system and experimental murine tumor. J Antibiot (Tokyo). 1985, 38(7):936-40. PMID: 3928564.

Dennis JW. Effects of swainsonine and polyinosinic:polycytidylic acid on murine tumor cell growth and metastasis. Cancer Res. 1986, ;46(10):5131-6. PMID: 3093060.

White SL , Schweitzer K, Humphries MJ, Olden K. Stimulation of DNA synthesis in murine lymphocytes by the drug swainsonine: immunomodulatory properties. Biochem Biophys Res Commun. 1988, 150(2):615-25. PMID: 3124836.

Humphries MJ , Matsumoto K, White SL, et. al. Augmentation of murine natural killer cell activity by swainsonine, a new antimetastatic immunomodulator. Cancer Res. 198, 48(6):1410-5. PMID: 3125963

Li Z , Huang Y, Dong F, et al. Swainsonine promotes apoptosis in human oesophageal squamous cell carcinoma cells in vitro and in vivo through activation of mitochondrial pathway. J Biosci. 2012, 37(6):1005-16. PMID: 23151791

Li Z , Xu X, Huang Y, et al. Swainsonine activates mitochondria-mediated apoptotic pathway in human lung cancer A549 cells and retards the growth of lung cancer xenografts. Int J Biol Sci. 2012, 8(3):394-405. doi: 10.7150/ijbs.3882. Epub 2012 Feb 24. PMID: 22393311 PMCID: PMC3291856 DOI: 10.7150/ijbs.3882

Sun JY , Yang H, Miao S, et al. Suppressive effects of swainsonine on C6 glioma cell in vitro and in vivo. Phytomedicine. 2009, 16(11):1070-4. doi: 10.1016/j.phymed.2009.02.012. Epub 2009 May 8. PMID: 19427771 DOI: 10.1016/j.phymed.2009.02.012.

You N , Liu W, Wang T, et al. Swainsonine inhibits growth and potentiates the cytotoxic effect of paclitaxel in hepatocellular carcinoma in vitro and in vivo. Oncol Rep. 2012, 28(6):2091-100. doi: 10.3892/or.2012.2035. Epub 2012 Sep 17. PMID: 22993037 DOI: 10.3892/or.2012.2035

Santos FM , Latorre AO, Hueza IM, et al. Increased antitumor efficacy by the combined administration of swainsonine and cisplatin in vivo. Phytomedicine. 2011, 18(12):1096-101. doi: 10.1016/j.phymed.2011.06.005. Epub 2011 Jul 16. PMID: 21763115 DOI: 10.1016/j.phymed.2011.06.005.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • C294458

    Chlorzoxazone

    Centrally acting muscle relaxant.

    ≥99%
  • R0109

    Racecadotril

    Enkephalinase inhibitor.

    ≥98%
  • P0346

    Palosuran Hydrochloride

    Urotensin II receptor antagonist.
  • M177531

    Menaquinone-9

    2-methyl-1,4-naphthoquinone derivative

    ≥99%
  • O2145

    Ofloxacin Hydrochloride

    Fluoroquinolone; topoisomerase IV and bacterial...

    ≥98%
  • P0932

    PCI-32765

    BTK and IL-2-inducible kinase inhibitor.

    ≥99%
  • D9752

    Dynasore

    Dynamin inhibitor.

    ≥98%
  • A5219

    Anethole Trithione

    Oltipraz analog, salivary gland secretion enhan...

    ≥98%
  • V0146

    Valsartan

    AT1 inhibitor.

    ≥98%
  • A0962

    Adrenocorticotropic Hormone (1-4)

    Endogenous peptide hormone fragment, involved i...

    ≥95%
  • S0168

    Saracatinib

    Src and Abl inhibitor.

    ≥98%
  • M964098

    Mycophenolate Mofetil

    Prodrug of the compound mycophenolic acid.

    ≥98%
  • R3197

    Rhynchophylline

    Oxyindole alkaloid found in Uncaria sinensis; h...

    ≥98%
  • C0255

    Cantharidin

    Toxin produced by Canarthis vesicatoria; PP1/2A...

    ≥98%
  • E543721

    Ensartinib

    A third-generation ALK inhibitor.

    ≥98%
  • Z0252

    Zanamivir

    Neuraminidase inhibitor.

    ≥98%
  • B8112

    Budesonide

    Steroid; glucocorticoid agonist.

    ≥97%
  • I0933

    Icilin

    TRPM8 activator, TRPV3 blocker.

    ≥98%
  • M5794

    Moxifloxacin Hydrochloride

    Fluoroquinolone; topoisomerase IV, topoisomeras...

    ≥98%
  • P2002

    PF-04691502 Dihydrate

    PI3K and mTOR inhibitor.

    ≥98%